Tag: NASDAQ:INCY

Finance

Mid Cap Volatile Stocks: Incyte Corporation (NASDAQ:INCY), Chart Industries (NASDAQ:GTLS), Diebold Inc (NYSE:DBD), NetSuite Inc (NYSE:N)

Incyte Corporation (NASDAQ:INCY) is scheduled to release its Q114 earnings data on Thursday, May 1st. Analysts expect Incyte Corporation (NASDAQ:INCY) to post earnings of ($0.17) per share and revenue of $97.70 million for the quarter. Incyte Corporation (NASDAQ:INCY) stock performance was 7.83% in last session and finished the day at $48.61. Traded volume was 1.94million shares in the last session and the average volume of … Continue reading Mid Cap Volatile Stocks: Incyte Corporation (NASDAQ:INCY), Chart Industries (NASDAQ:GTLS), Diebold Inc (NYSE:DBD), NetSuite Inc (NYSE:N)

Colin Pettis
Finance

Healthcare Bullish Stocks: Dyax Corp. (NASDAQ:DYAX), Incyte Corporation (NASDAQ:INCY), ISIS Pharmaceuticals (NASDAQ:ISIS), NPS Pharmaceuticals (NASDAQ:NPSP)

Dyax Corp. (NASDAQ:DYAX) was a big mover last session, as the company saw its shares rise nearly 6% on the day. This rally higher can be attributable to solid volume with far more shares changing hands than in a normal session. Dyax Corp. (NASDAQ:DYAX) currently has a Zacks Rank #3 (Hold). Dyax Corp. (NASDAQ:DYAX) stock performance was 5.90% in last session and finished the day … Continue reading Healthcare Bullish Stocks: Dyax Corp. (NASDAQ:DYAX), Incyte Corporation (NASDAQ:INCY), ISIS Pharmaceuticals (NASDAQ:ISIS), NPS Pharmaceuticals (NASDAQ:NPSP)

Jason Knox
Finance

Biotech Gainers: Xencor Inc (NASDAQ:XNCR), Pacific Biosciences of California (NASDAQ:PACB), Endocyte (NASDAQ:ECYT), Incyte Corporation (NASDAQ:INCY)

Xencor, Inc. (NASDAQ:XNCR) is unchanged at $11.73, with 934,368 shares traded. As reported by Zacks, the current mean recommendation for XNCR is in the “strong buy range”. Xencor Inc (NASDAQ:XNCR) stock performance was 11.18% in last session and finished the day at $11.73. Traded volume was 1.86million shares in the last session and the average volume of the stock remained 132.02K shares. Xencor Inc (NASDAQ:XNCR) … Continue reading Biotech Gainers: Xencor Inc (NASDAQ:XNCR), Pacific Biosciences of California (NASDAQ:PACB), Endocyte (NASDAQ:ECYT), Incyte Corporation (NASDAQ:INCY)

Kevin Long
Finance

Biotech Volatile Stocks: Incyte Corporation (NASDAQ:INCY), Halozyme Therapeutics (NASDAQ:HALO), Sangamo Biosciences (NASDAQ:SGMO), Nektar Therapeutics (NASDAQ:NKTR)

The only therapy currently approved by the Food and Drug Administration to treat myelofibrosis, a disorder where abnormal blood cells build up inside a patient’s bone marrow, is Incyte (NASDAQ:INCY) and Novartis’ Jakafi (known as Jakavi outside the U.S.), which is a JAK2 inhibitor. JAK2 is an enzyme that plays a key role in signal transduction; therefore, blocking JAK2 can inhibit the development cytokines that … Continue reading Biotech Volatile Stocks: Incyte Corporation (NASDAQ:INCY), Halozyme Therapeutics (NASDAQ:HALO), Sangamo Biosciences (NASDAQ:SGMO), Nektar Therapeutics (NASDAQ:NKTR)

Mark Doerr
Finance

Biotech Losers: ACADIA Pharmaceuticals (NASDAQ:ACAD), Incyte Corporation (NASDAQ:INCY), Galena Biopharma (NASDAQ:GALE), Alexion Pharmaceuticals (NASDAQ:ALXN)

Board of Directors of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) adopted an updated annual incentive cash compensation program for its executive officers to be effective beginning with 2014. The description of this program is set forth in Exhibit 99.1 and is incorporated herein by reference. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stock performance was -6.80% in last session and finished the day at $24.27. Traded volume was 3.59million shares … Continue reading Biotech Losers: ACADIA Pharmaceuticals (NASDAQ:ACAD), Incyte Corporation (NASDAQ:INCY), Galena Biopharma (NASDAQ:GALE), Alexion Pharmaceuticals (NASDAQ:ALXN)

Colin Pettis